Bristol-myers Squibb Compnay

Bayer Healthcare LLC

Viiv Healthcare UK (no. 4) Limited

Viiv Healthcare UK (no.5) Limited

Bayer Intellectual Property Gmbh

Bayer Schering Pharma Ag

Viiv Healthcare UK Limited

Viiv Healthcare (no.5) Limited

Zheng Liu

Alicia Regueiro-Ren

Nicholas A Meanwell

Jacob Swidorski

Sing-Yuen Sit

Jie Chen

Ny Sin

Yan Chen

Richard A Hartz

Brian Lee Venables

Tao Wang

Lawrence G Hamann

Zhongxing Zhang

Barton W Phillips

Steven R Magnuson

John F Kadow

Stephen J O'Connor

Chengzhi Zhang

Kyle E Parcella

Zhonghua Zhang

David J Carini

Julie A Dixon

Zhiwei Yin

Yasutsugu Ueda

Uday R Khire

Qian Zhao

Gaetan H Ladouceur

Mario Lobell

Chetan Padmakar Darne

Yamin Wang

Martin Michels

Jason S Newcom

Li Xu

Zhenqiu Hong

Brent Chandler

Harold C E Kluender

Barry L Johnson

Furahi Achebe

Lei Wang

Kristen M Allegue

Wenying Li

Animesh Goswami

Zhiwei Guo

Tindy Li

Thomas P Tully

Harold Kluender

Tandy Li

Kanwar Sidhu

Nicolas A Meanwell

Chetan P Darne

Jason Newcom

Gaetan Ladouceur

Kristen Allegue

Julie Dixon

Stephen J O'connor

Alicia Regueiro-ren

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I: with X selected from Ccycloalkyl, Ccycloalkenyl, Cspirocycloalkyl, Cspirocycloalkenyl, Coxacycloalkyl, Cdioxacycloalkyl, Coxacycloalkenyl, Cdioxacycloalkenyl, Ccyclodialkenyl, Coxacyclodialkenyl, Coxaspirocycloalkyl and Coxaspirocycloalkenyl ring, such that X is substituted with A, wherein A is &#x2014;Calkyl-halo. These compounds are useful for the treatment of HIV and AIDS.

Triterpenoids with HIV maturation inhibitory activity

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I and II: These compounds are useful for the treatment of HIV and AIDS.

Oxolupene derivatives

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, betulinic acid derivaties that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III: These compounds are useful for the treatment of HIV and AIDS.

Betulinic acid derivatives with HIV maturation inhibitory activity

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, alkyl and alkenyl C-3 modified betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II, III and IV: a compound of Formula I     The compounds are useful for the treatment of HIV and AIDS.

C-3 alkyl and alkenyl modified betulinic acid derivatives

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 bicyclic amines of triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III: These compounds are useful for the treatment of HIV and AIDS.

C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-17 and C-3 modified triterpenoids that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formulas I, II and III: These compounds are useful for the treatment of HIV and AIDS.

C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, modified C-3 and C-28 betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS.

C-28 amides of modified C-3 betulinic acid derivatives as HIV maturation inhibitors

Compounds of Formula I: that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS.

Betulinic acid derivatives with antiviral activity

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, modified C-3 betulinic acid and other structurally related natural products derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS.

Modified C-3 betulinic acid derivatives as HIV maturation inhibitors

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, C-28 amines of C-3 modified betulinic acid derivatives that possess unique antiviral activity are provided as HIV maturation inhibitors. These compounds are useful for the treatment of HIV and AIDS. In particular, the following compounds are provided herein, including pharmaceutically acceptable salts thereof: a compound of formula I a compound of formula II and a compound of formula III 

C-28 amines of C-3 modified betulinic acid derivatives as HIV maturation inhibitors

This invention relates to compounds of Formula (I), wherein the variables are as disclosed in the specification, to pharmaceutical compositions containing them, to methods of making the compounds and pharmaceutical compositions, and to methods of using the compounds and pharmaceutical compositions for treating or preventing disorders, in particular cancer.

Tetrahydropyridothienopyrimidine compounds and methods of use thereof

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, diketopiperidine derivatives that possess unique antiviral activity are provided. These compounds are useful for the treatment of HIV and AIDS.

Diketopiperidine derivatives as HIV attachment inhibitors

This invention relates to novel pyrrozolotriazine compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.

Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

Growing community of inventors

Beacon Falls, CT, United States of America

Zheng Liu